| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57f3e2af72b2933c004ed61dfccaaee1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05570762629e51b58e4479b61fbebe76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b720053045d21f1ef5ac09d6aeba592f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e37b80463ff4a66db9a522b4f60d8320
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e51f0251f7b2e31c9b3da575dc16789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b53834d4f4a0366b5036ed7e37d24d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7056fa149e5397a45644908590018b80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a09eaf2b208c029beffcb6560c32ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc744e9b3eaa40f5d6da85348d7dbd69 |
| publicationDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2013318618-B2 |
| titleOfInvention |
Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker |
| abstract |
Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib. |
| priorityDate |
2012-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |